
Pacira BioSciences, Inc.
Pacira BioSciences, Inc. (PCRX) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · PCRX · as of Jun 8, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
15
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Pacira BioSciences, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
PCRX insider buying and selling by quarter
PCRX insider selling · PCRX insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · PCRX ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
PCRX executive sell shares · PCRX board member insider trading · PCRX insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Jun 3, 2026 | RIKER LAUREN Senior Vice President, Finance | Other | 3,187 | $71K | Form 4 |
| Jun 3, 2026 | SLONIN JONATHAN Chief Medical Officer | Other | 4,728 | $106K | Form 4 |
| Jun 3, 2026 | WILLIAMS KRISTEN Chief Administrative Officer | Other | 8,528 | $190K | Form 4 |
| Jun 4, 2026 | WILLIAMS KRISTEN Chief Administrative Officer | Sale | 10,259 | $228K | Form 4 |
| Apr 23, 2026 | Cross Shawn CFO | Option | 12,941 | $213K | Form 4 |
| Apr 23, 2026 | Cross Shawn CFO | Sale | 12,941 | $326K | Form 4 |
| Apr 20, 2026 | Cross Shawn CFO | Option | 7,714 | $127K | Form 4 |
| Apr 21, 2026 | Cross Shawn CFO | Option | 2,845 | $47K | Form 4 |
| Apr 22, 2026 | Cross Shawn CFO | Option | 1,500 | $25K | Form 4 |
| Apr 20, 2026 | Cross Shawn CFO | Sale | 7,714 | $194K | Form 4 |
| Apr 22, 2026 | Cross Shawn CFO | Sale | 1,500 | $38K | Form 4 |
| Mar 17, 2026 | SLONIN JONATHAN Chief Medical Officer | Sale | 3,261 | $74K | Form 4 |
| Mar 17, 2026 | Froimson Mark Director | Sale | 500 | $11K | Form 4 |
| Feb 11, 2026 | Cross Shawn CFO | Award | 49,091 | — | Form 4 |
| Feb 11, 2026 | WILLIAMS KRISTEN Chief Administrative Officer | Award | 54,546 | — | Form 4 |
| Feb 11, 2026 | Teehan Brendan Chief Commercial Officer | Award | 51,714 | — | Form 4 |
| Feb 11, 2026 | RIKER LAUREN Senior Vice President, Finance | Award | 19,273 | — | Form 4 |
| Feb 11, 2026 | SLONIN JONATHAN Chief Medical Officer | Award | 54,546 | — | Form 4 |
| Feb 11, 2026 | Lee Frank D. CEO · Director | Award | 261,818 | — | Form 4 |
| Jan 30, 2026 | RIKER LAUREN Senior Vice President, Finance | Other | 2,751 | $57K | Form 4 |
| Feb 2, 2026 | RIKER LAUREN Senior Vice President, Finance | Sale | 4,000 | $83K | Form 4 |
| Jan 30, 2026 | WILLIAMS KRISTEN Chief Administrative Officer | Other | 17,134 | $352K | Form 4 |
| Feb 2, 2026 | WILLIAMS KRISTEN Chief Administrative Officer | Sale | 13,137 | $270K | Form 4 |
| Jan 30, 2026 | SLONIN JONATHAN Chief Medical Officer | Other | 6,168 | $127K | Form 4 |
| Jan 30, 2026 | Teehan Brendan Chief Commercial Officer | Other | 5,182 | $106K | Form 4 |
RIKER LAUREN
Senior Vice President, Finance
Date
Jun 3
Shares
3,187
Price
$22.32
Value
$71K
SLONIN JONATHAN
Chief Medical Officer
Date
Jun 3
Shares
4,728
Price
$22.32
Value
$106K
WILLIAMS KRISTEN
Chief Administrative Officer
Date
Jun 3
Shares
8,528
Price
$22.32
Value
$190K
WILLIAMS KRISTEN
Chief Administrative Officer
Date
Jun 4
Shares
10,259
Price
$22.27
Value
$228K
SLONIN JONATHAN
Chief Medical Officer
Date
Mar 17
Shares
3,261
Price
$22.82
Value
$74K
WILLIAMS KRISTEN
Chief Administrative Officer
Date
Feb 11
Shares
54,546
Price
—
Value
—
RIKER LAUREN
Senior Vice President, Finance
Date
Feb 11
Shares
19,273
Price
—
Value
—
RIKER LAUREN
Senior Vice President, Finance
Date
Jan 30
Shares
2,751
Price
$20.54
Value
$57K
RIKER LAUREN
Senior Vice President, Finance
Date
Feb 2
Shares
4,000
Price
$20.81
Value
$83K
WILLIAMS KRISTEN
Chief Administrative Officer
Date
Jan 30
Shares
17,134
Price
$20.54
Value
$352K
WILLIAMS KRISTEN
Chief Administrative Officer
Date
Feb 2
Shares
13,137
Price
$20.53
Value
$270K
SLONIN JONATHAN
Chief Medical Officer
Date
Jan 30
Shares
6,168
Price
$20.54
Value
$127K
Teehan Brendan
Chief Commercial Officer
Date
Jan 30
Shares
5,182
Price
$20.54
Value
$106K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About PCRX insider trading
PCRX insider trades
Pacira BioSciences, Inc. (PCRX) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Cross Shawn (CFO), SLONIN JONATHAN (Chief Medical Officer), RIKER LAUREN (Senior Vice President, Finance). Over the past 12 months, 5 insiders have filed transactions with the SEC. PCRX insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Pacira BioSciences, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
PCRX insider trading · 5 questionsThe insiders of Pacira BioSciences, Inc. (PCRX) include executives and directors such as Cross Shawn (CFO), SLONIN JONATHAN (Chief Medical Officer), RIKER LAUREN (Senior Vice President, Finance), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026